JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 121 filers reported holding JUNO THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 1.68 and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $73,368,000 | +61.0% | 1,605,070 | +58.0% | 0.02% | +41.7% |
Q3 2017 | $45,582,000 | +57.7% | 1,016,077 | +5.1% | 0.01% | +71.4% |
Q2 2017 | $28,898,000 | +45.0% | 966,781 | +7.6% | 0.01% | +40.0% |
Q1 2017 | $19,931,000 | +515.2% | 898,160 | +422.6% | 0.01% | +400.0% |
Q4 2016 | $3,240,000 | -69.6% | 171,851 | -51.6% | 0.00% | -66.7% |
Q3 2016 | $10,664,000 | -22.6% | 355,365 | -0.9% | 0.00% | -25.0% |
Q2 2016 | $13,782,000 | +109.8% | 358,523 | +107.9% | 0.00% | +100.0% |
Q1 2016 | $6,570,000 | -67.1% | 172,478 | -62.1% | 0.00% | -71.4% |
Q4 2015 | $19,993,000 | +140.8% | 454,688 | +122.8% | 0.01% | +133.3% |
Q3 2015 | $8,304,000 | +201.3% | 204,086 | +294.9% | 0.00% | – |
Q2 2015 | $2,756,000 | +134.6% | 51,680 | +166.9% | 0.00% | – |
Q1 2015 | $1,175,000 | – | 19,361 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
SIB LLC | 100,000 | $4,571,000 | 3.28% |
PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |